143 results on '"Kroese, F. G. M."'
Search Results
2. Immuuntherapie van kanker
3. Transplantatie
4. Auto-immuniteit
5. Allergie en overgevoeligheid
6. Immuundeficiëntie
7. Regionale immuniteit
8. Humorale immuniteit
9. Barrières en aangeboren immuniteit
10. Lymfocytenvorming
11. Cellulaire immuniteit
12. Bouw en functie van perifere lymfoïde organen
13. Ontsteking
14. Antigeenherkenning en antigeenpresentatie
15. De afweer van de mens
16. OP0113 GENOME-WIDE ASSOCIATION STUDY OF Ro/SSA+ AND Ro/SSA-SJÖGREN’S CASES IN THE SJÖGREN’S GENETIC NETWORK (SGENE) DEMONSTRATES DIVERGENT GENETIC ARCHITECTURE IN PATIENT SUBPHENOTYPES
17. OP0226 POTENTIAL VALUE OF THE BLOOD INTERFERON SIGNATURE IN THE DIAGNOSIS OF PEDIATRIC-ONSET SJÖGREN’S DISEASE PATIENTS
18. POS0807 IMPROVEMENT OF BONE MINERAL DENSITY AND NEW VERTEBRAL FRACTURES DURING 8 YEARS OF TNF-Α INHIBITION IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS
19. POS0265 ESTABLISHING CONSISTENCY IN THE DIGITAL IMAGING ANALYSIS OF HISTOLOGICAL PARAMETERS IN SJOGREN’S DISEASE
20. AB0822 LACRIMAL GLAND ULTRASOUND DEMONSTRATES GOOD INTEROBSERVER RELIABILITY
21. Translational Research in Sjögren’s Syndrome
22. Vorming en expressie van antigeenreceptoren op T- en B-lymfocyten
23. Bouw en functie van perifere lymfoïde organen
24. AB0520 TREATMENT OF PRIMARY SJÖGREN’S SYNDROME BY INHIBITING FCRN: A PHASE 2 RANDOMIZED, PLACEBO CONTROLLED, DOUBLE-BLIND, PROOF OF CONCEPT STUDY WITH EFGARTIGIMOD
25. POS0163 PERFORMANCE OF THE SALIVARY GLAND ULTRASONOGRAPHY OMERACT SCORE IN THE ACR-EULAR CLASSIFICATION CRITERIA FOR SJÖGREN’S SYNDROME
26. POS0430 THE EXPANDED CD21LOW B CELL SUBPOPULATION IN ANKYLOSING SPONDYLITIS CONSISTS MAINLY OF UNMUTATED ANTIGEN-INEXPERIENCED CELLS THAT ARE CLONALLY RELATED TO MEMORY B CELLS AND PLASMABLASTS
27. POS0436 INCREASED EXPRESSION OF PATHWAYS INVOLVED IN B CELL ACTIVATION IN PATIENTS WITH ANKYLOSING SPONDYLITIS
28. POS1446 VARIATION IN SYSTEMIC DISEASE ACTIVITY MEASURED WITH ESSDAI IN A PROSPECTIVE LONGITUDINAL COHORT OF PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME WITHOUT IMMUNOSUPPRESSIVE TREATMENT
29. POS1456 DIAGNOSTIC ACCURACY OF THE LABIAL SALIVARY GLAND BIOPSY INCREASES WHEN OTHER HISTOPATHOLOGICAL PARAMETERS BESIDES FOCUS SCORE ARE TAKEN INTO ACCOUNT IN PRIMARY SJÖGREN’S SYNDROME
30. Patient acceptable symptom state (PASS) in patients with primary Sjögren's syndrome in daily clinical practice
31. Digital image analysis of intraepithelial B-lymphocytes as an objective alternative to assess lymphoepithelial lesions in salivary glands of Sjögren's syndrome patients
32. Reduced central nervous system drive in primary Sjögren’s syndrome is associated with objective decline in motor performance and self-reported fatigue
33. Peritoneal B-1 Cells Switch in vivo to IgA and these IgA Antibodies can bind to Bacteria of the Normal Intestinal Microflora
34. A more mature plasma cell and plasmablast compartment is associated with disease manifestation in primary Sjogren's syndrome
35. POS0454 DIGITAL IMAGE ANALYSIS OF INTRAEPITHELIAL B-LYMPHOCYTES AS AN OBJECTIVE ALTERNATIVE TO ASSESS LYMPHOEPITHELIAL LESIONS IN SALIVARY GLANDS OF SJÖGREN’S SYNDROME PATIENTS
36. POS0948 SIX YEARS TREATMENT WITH TNF-α INHIBITORS DOES NOT LEAD TO LONG-TERM CONTINUOUS HYPERMINERALIZATION IN PATIENTS WITH ANKYLOSING SPONDYLITIS
37. POS0457 LABIAL AND PAROTID SALIVARY GLAND HISTOPATHOLOGY IN PRIMARY SJÖGREN’S SYNDROME
38. POS0738 IMMUNOGENICITY AND SAFETY OF COVID-19 VACCINATION IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME
39. OP0010 A MORE MATURE PLASMA CELL AND PLASMABLAST COMPARTMENT IS ASSOCIATED WITH DISEASE MANIFESTATION IN PRIMARY SJÖGREN’S SYNDROME
40. POS0758 REDUCED CENTRAL NERVOUS SYSTEM DRIVE IN PRIMARY SJÖGREN’S SYNDROME IS ASSOCIATED WITH OBJECTIVE DECLINE IN MOTOR PERFORMANCE AND SELF-REPORTED FATIGUE
41. POS0754 PATIENT ACCEPTABLE SYMPTOM STATE (PASS) IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME IN DAILY CLINICAL PRACTICE
42. Differences in presentation between paediatric- and adult-onset primary Sjögren's syndrome patients
43. Germinal Center Reaction and B Lymphocytes: Morphology and Function
44. COMPOSITE OF RELEVANT ENDPOINTS IN SJOGREN'S SYNDROME (CRESS): A COMPREHENSIVE TOOL FOR CLINICAL TRIALS
45. Abatacept treatment reduces disease activity in early primary Sjögrenʼs syndrome (open-label proof of concept ASAP study)
46. CD27-CD38(low)CD21(low) B-CELLS ARE INCREASED IN ANKYLOSING SPONDYLITIS
47. POS0412 CD21-/LOW B-CELLS ARE INCREASED IN PATIENTS WITH ANKYLOSING SPONDYLITIS
48. OP0130 COMPOSITE OF RELEVANT ENDPOINTS IN SJÖGREN’S SYNDROME (CRESS): A COMPREHENSIVE TOOL FOR CLINICAL TRIALS
49. OP0308 SENESCENT PROGENITOR CELLS IN THE SKIN OF LUPUS PATIENTS
50. EULAR Sjögrenʼs Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.